# Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

> **NCT06577532** · EARLY_PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Pancreatic Neoplasms
- Other Solid Tumors

## Interventions

- **DRUG:** ABO2102
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06577532
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2026-12
- **Final completion:** 2027-08
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577532, "Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06577532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*